X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.
Lead Product(s): Methylphenidate
Therapeutic Area: Psychiatry/Psychology Product Name: Cotempla
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
Under the agreement, Medomie will commercialize Adzenys XR-ODT (amphetamine) and Cotempla XR-ODT (methylphenidate) in Israel and the Palestinian Authority.
Lead Product(s): Amphetamine
Therapeutic Area: Psychiatry/Psychology Product Name: Adzenys XR
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Medomie
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 31, 2023
Details:
XR-ODT is FDA-Approved as Bioequivalent to Adderall XR is the only FDA-approved, extended-release, orally-disintegrating tablet formulation of amphetamine,indicated for the treatment of ADHD in patients six years and older.
Lead Product(s): Amphetamine
Therapeutic Area: Psychiatry/Psychology Product Name: Adzenys XR-ODT
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
AR101 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K and AKT pathways.
Lead Product(s): Enzastaurin
Therapeutic Area: Genetic Disease Product Name: AR101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2022
Details:
The Company intends to use the net proceeds from the Offering for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome (VEDS).
Lead Product(s): Enzastaurin
Therapeutic Area: Genetic Disease Product Name: AR101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Canaccord Genuity
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 15, 2022
Details:
Acerus will acquire all remaining rights to Natesto in the United States from Aytu. Acerus will assume all product responsibilities associated with Natesto.
Lead Product(s): Testosterone
Therapeutic Area: Endocrinology Product Name: Natesto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Acerus Pharmaceuticals
Deal Size: $7.5 million Upfront Cash: $7.5 million
Deal Type: Divestment April 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
